乳房假体周围感染管理的系统评价与荟萃分析
该系统评价与荟萃分析检索MEDLINE、EMBASE和CENTRAL数据库1946至2019年9月的临床研究,纳入19篇文献共1044例患者,评估感染乳房假体不同处理方式的疗效。结果显示轻度感染单用抗生素的成功率为81.41%,手术挽救的成功率为84.56%,而取出假体后仅39.02%再植入,感染复发率为4.99%。
要点
- 轻度感染单用抗生素成功率高,81.41%无需手术。
- 手术挽救感染假体成功率84.56%,可保留假体无复发。
- 取出假体后再植入率仅39.02%,感染复发率4.99%。
核心结论
- 本研究汇总了感染乳房假体管理的现有证据,可辅助决策和患者教育,但缺乏1级证据。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、EMBASE和CENTRAL数据库1946年至2019年9月的原始临床研究。
- 共纳入19篇文章,涉及1044例患者。
主要发现
- 29.00%(95%CI 11.51%–50.58%)的轻度感染患者仅用抗生素治疗,其中81.41%(95%CI 57.82%–96.63%)成功治愈无需手术。
- 39.01%(95%CI 21.41%–58.23%)的患者接受感染假体手术挽救,其中84.56%(95%CI 74.92%–92.20%)成功保留假体且无感染复发。
- 35.01%(95%CI 27.01%–43.57%)的患者取出感染假体,其中仅39.02%(95%CI 23.93%–55.28%)后期再植入新假体,4.99%(95%CI 1.66%–9.99%)感染复发需取出假体。
- 最常见并发症为包膜挛缩,发生于10.78%(95%CI 4.41%–19.49%)的患者。
临床怎么用
- 轻度感染可优先尝试单纯抗生素治疗,成功率较高。
- 手术挽救适用于希望保留假体的患者,成功率高。
- 取出假体后再植入率较低,需告知患者感染复发风险。
局限性
- 现有数据缺乏1级证据。
- 未报告生活质量和成本影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current management of an infected breast implant is varied. This systematic review and meta-analysis aim to synthesise the current evidence and establish the efficacy of the various managements of infected breast implants. METHODS: A comprehensive search in the MEDLINE, EMBASE and CENTRAL databases was conducted for primary clinical studies that report on the management of infected breast implants from 1946 to September 2019. The primary outcome measure was the proportion of patients with successful treatment. RESULTS: Nineteen articles that involve 1044 patients were included. Overall, 29.00% (95% CI = from 11.51% to 50.58%) of the patients with mild infection were treated exclusively with antibiotics, of which, 81.41% (95% CI = from 57.82% to 96.63%) were successfully treated without the need for surgical intervention. Another 39.01% (95% CI = from 21.41% to 58.23%) of the patients underwent surgical salvage of the infected breast implants, of which 84.56% (95% CI = from 74.92% to 92.20%) successfully retained the salvaged implants without infection recurrence. Meanwhile, 35.01% (95% CI = from 27.01% to 43.57%) of the patients underwent explantation of the infected breast implant, of which, only 39.02% (95% CI = from 23.93% to 55.28%) had re-insertion of a new implant on a later date and 4.99% (95% CI = from 1.66% to 9.99%) of these patients had recurrence of infection requiring removal of the infected implant. The commonest complication was capsular contracture, which was reported in 10.78% (95% CI = from 4.41% to 19.49%) of the patients. Changes in the quality of life and cost implications were not reported. CONCLUSION: This study consolidates current available evidence on the management of infected breast implants, which could assist decision-making and improve patient education; however, current data are limited because of the lack of level-1 evidence.
引用
- Kanapathy M, Faderani R, Arumugam V, et al. Management of periprosthetic breast infection: a systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2021. PMID: 34257035. doi:10.1016/j.bjps.2021.05.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。